Physician profile
Jack C Moore
NPI 1164443529
$1,911.12
in general payments reported to CMS, 2019-2025
28 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $250 · 2022: $14.06 · 2023: $490 · 2024: $552 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.98 | 2023-2025 | |
| Pfizer INC. | $184.27 | 2020-2024 | |
| Novo Nordisk INC | $140.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $94.01 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $88.30 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Phathom Pharmaceuticals, INC. | $85.76 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.34 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $79.88 | 2019-2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $68.76 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.64 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $51.14 | 2020-2023 | Shingrix, Arexvy |
| Mylan Specialty L.P. | $44.59 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $38.12 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $36.47 | 2024 | Nuzyra |
| Abiomed | $32.88 | 2024 | Impella |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.07 | 2019-2022 | |
| Ethicon INC. | $28.62 | 2024 | Monarch Platform |
| Merck Sharp & Dohme LLC | $28.11 | 2019-2020 | |
| Dynavax Technologies Corporation | $22.20 | 2025 | Heplisav-B |
| Esperion Therapeutics, INC. | $19.67 | 2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.47 | 2025 | Relistor |
| Bayer Healthcare Pharmaceuticals INC. | $17.86 | 2023 | |
| Amarin Pharma, INC. | $17.75 | 2019 | |
| Circassia INC. | $17.63 | 2019 | |
| Radius Health, INC. | $16.39 | 2023 | Tymlos |
| Neurelis, INC. | $14.46 | 2024 | Valtoco |
| Eisai INC. | $12.13 | 2020 | |
| Allergan, INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.